Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Long-Term Investments (2024 - 2025)

Outlook Therapeutics (OTLK) has disclosed Long-Term Investments for 2 consecutive years, with $513549.0 as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Investments fell 22.18% to $513549.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $513549.0, a 22.18% decrease, with the full-year FY2025 number at $552183.0, changed N/A from a year prior.
  • Long-Term Investments was $513549.0 for Q4 2025 at Outlook Therapeutics, down from $552183.0 in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $659895.0 in Q4 2024 to a low of $513549.0 in Q4 2025.